Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of CN-105 peptide injection in acute ischemic stroke
CTR20244468Phase 2Active
- Sponsor
- Kunpeng Tailing
- Start
- Jan 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing CN-105 peptide injection with Placebo mimic injection (2 arms). Primary endpoints: Incidence and severity of adverse events, All-cause mortality and 2 more. Started Jan 2026; status: active.
02
Drugs
CN-105
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20244468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244468.